Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Truly amazing you still don't understand that Cotropia was part of the ENZC scam."
So, is there going to be some kind of class-action lawsuit against Cotropia and others in connection with the scam?
"I called out the idiots that posted Cotropia had filed a lawsuit against Fauci about Clone 3 and won - which wasn't close to being true."
How do you know that this is not true?
Who is KOP?
There is a discrepancy in the disclosure for the year ending on 12/31/23.
Here is the disclosure:
https://www.otcmarkets.com/otcapi/company/financial-report/398912/content
On page 1 of the disclosure, it says that there are 3,187,974,957 shares of ENZC common stock outstanding as of 12/31/23.
However, on page 3 of the disclosure, it says that there are 3,172,974,957 shares of ENZC common stock outstanding as of 12/31/23.
So, which number of shares is correct?
The following web page shows the number of ENZC shares outstanding for the most recent business day: https://www.otcmarkets.com/stock/ENZC/security
For example, if I go to that web page on May 5, 2024, then that web page will show me the number of ENZC shares outstanding on May 3, 2024.
However, I want to see how many ENZC shares outstanding there were months before the most recent business day. So, if I want to see how many ENZC shares outstanding there were on 9/15/23, how do I do that?
Prior to September 15, 2023, the Series A Preferred shares of Enzolytics (that is, the Enzolytics shares with voting control) were owned as follows:
Zhabilov Trust - 18,900,000 shares - 31.50% of shares
Charles Cotropia - 14,917,500 shares - 24.86% of shares
Joseph Cotropia - 14,917,500 shares - 24.86% of shares
Gaurav Chandra - 5,265,000 shares - 8.78% of shares
Phil Phelizian - 6,000,000 shares - 10.00% of shares
source:
https://www.otcmarkets.com/otcapi/company/financial-report/387028/content (pages 28 - 29)
On September 15, 2023, Enzolytics closed the Business Combination Agreement with SAGA for the sale of VIRO and BGEN to SAGA. To facilitate the SAGA transaction, Charles Cotropia, Joseph Cotropia, and Guarav Chandra surrendered all of their Series A Preferred shares, and the Zhabilov Trust surrendered 11,700,000 of its Series A Preferred shares. As a result, the Series A Preferred shares of Enzolytics (that is, the Enzolytics shares with voting control) were owned as
follows:
Zhabilov Trust - 7,200,000 shares - 54.55% of shares
Phil Phelizian - 6,000,000 shares - 45.45% of shares
source:
https://www.otcmarkets.com/otcapi/company/financial-report/387028/content (page 42)
According to my Enzolytics SAFE (Simple Agreement for Future Equity), I am supposed to receive Enzolytics Common Stock if a "change of control" occurs. The SAFE defines "change of control" as follows:
“change of control” means (i) a transaction or series of related transactions in which any “person” or “group” (within the meaning of Section 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended), becomes the “beneficial owner” (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended), directly or indirectly, of more than 50% of the outstanding voting securities of the Company having the right to vote for the election of members of the Company’s board of directors, (ii) any reorganization, merger or consolidation of the Company, other than a transaction or series of related transactions in which the holders of the voting securities of the Company outstanding immediately prior to such transaction or series of related transactions retain, immediately after such transaction or series of related transactions, at least a majority of the total voting power represented by the outstanding voting securities of the Company or such other surviving or resulting entity or (iii) a sale, lease or other disposition of all or substantially all of the assets of the Company.
Given the above information about who owns how many shares, it seems that, on September 15, 2023, the "group" known as the Zhabilov Trust became the "beneficial owner" of more than 50% of the outstanding voting securities. Therefore, on September 15, 2023, condition (i) of the definition of "change of control" was satisfied. Therefore, I am supposed to get Enzolytics Common Stock. In fact, everyone who owns an Enzolytics SAFE is supposed to get Enzolytics Common Stock.
So, am I correct in thinking that everyone who owns an Enzolytics SAFE is supposed to get Enzolytics Common Stock?
Also, why did the Cotropias, Chandra, and the Zhabilov Trust have to give up all of those Series A Preferred shares? How did their giving up the shares facilitate the SAGA transaction?
ENZC's securities lawyer is Morgan E. Petitti.
Her contact information is as follows:
118 W. Streetsboro Road
Suite #317
Hudson, OH 44236
330 - 697 - 8548
pettitilaw@gmail.com
sources:
https://www.otcmarkets.com/stock/ENZC/profile
https://www.otcmarkets.com/financialReportViewer?symbol=OSCI&id=376096 (page 15)
ENZC's accounting firm is Fruci & Associates.
This firm's contact information is as follows:
802 N. Washington St.
Spokane, WA 99201
509 - 624 - 9223
877 - 264 - 0486
mail@fruci.com
sources:
https://www.otcmarkets.com/stock/ENZC/profile
https://www.fruci.com/contact
I strongly suggest that we flood the lawyer's phone and email inbox and the accounting firm's phones and email inbox with our complaints about ENZC's behavior. Hopefully, pressure from a LOT of irate and angry investors will cause the lawyer and the accounting firm to pressure their clients (the people behind ENZC) to give the investors some honest answers about what is going on with ENZC. We should make sure that the lawyer and the accounting firm know that, if the people behind ENZC are doing something illegal, then the people behind ENZC, and possibly the lawyer and the accounting firm as well, can be brought up on criminal charges and/or sued in class-action lawsuits.
On May 1, 2024, I tried to send an email to the address info@enzolytics.com. I received an error message saying that the email address info@enzolytics.com does not exist.
"techs say 006 break"
What does this mean?
"ENZC management should have put out a PR letting everyone (general public and sharehlders) know what their plan was..."
If that had happened, then the general public (that is, all non-shareholders) would have developed a negative opinion of ENZC, and the shareholders would not have had any buyers for their shares, and the shares would have plunged in value.
"The link you provided was for fiscal year 2011 to 2012."
How do I find out the CURRENT number of shares outstanding?
Was ENZC supposed to notify ONLY the shareholders (and not the general public) about these future developments, so that the shareholders would have the chance to sell ENZC shares before the shares plunged in price?
If yes, would that not be illegal insider trading?
Let me see if I understand this situation.
Charles Cotropia, Joseph Cotropia, and Chandra, collectively, have more ENZC shares than Harry Z. But Harry Z is now claiming that he is in control of ENZC and that the Cotropias and Chandra are not in control. Harry Z's claim is false, and the Cotropias and Chandra may sue him for control of ENZC.
Is my understanding correct?
If Harry Z does take control of ENZC, would that constitute a change of control as described in the Enzolytics SAFE?
To refresh everyone's memory, the SAFE defines "change of control" as follows:
“change of control” means (i) a transaction or series of related transactions in which any “person” or “group” (within the meaning of Section 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended), becomes the “beneficial owner” (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended), directly or indirectly, of more than 50% of the outstanding voting
securities of the Company having the right to vote for the election of members of the Company’s board of directors, (ii) any reorganization, merger or consolidation of the Company, other than a transaction or series of related transactions in which the holders of the voting securities of the Company outstanding immediately prior to such transaction or series of related transactions retain, immediately after such transaction or seriesof related transactions, at least a majority of the total voting power represented by the outstanding voting securities of the Company or such other surviving or resulting entity or (iii) a sale, lease or other disposition of all or substantially all of the assets of the Company.
"I suspect Harry will not go after the IP because the party of four (Charles, Harry, Chandra and Joe) has made a pact and divided up the IPs and wealth among themselves."
If the party of four, collectively, owned a majority of the shares of ENZC, then did these four people not have the legal right to divide up the ENZC IP in any way they wished?
I was asked how well Charles had run BioClonetics before the merger with Enzolytics. I invested into BioClonetics in 2017. BioClonetics merged with Enzolytics in late 2020. From the time I invested in 2017 to the end of 2020, Charles was great at providing updates.
The link that I provided pointed to the number of Shares Outstanding. I used that number to calculate how many shares I would get in a change of control.
1) As head of BioClonetics, Charles gave many updates on what was happening with the company. So, from the update standpoint, Charles was very good.
2) number of shares of Enzolytics
Common Stock after change of control
= purchase amount / liquidity price
= purchase amount / (valuation cap / number of shares outstanding)
= $200 / ($6,000,000 / 2,440,000,000)
= 81333 and 1/3 shares
source for number of shares outstanding - https://finance.yahoo.com/quote/ENZC/key-statistics?p=ENZC (Shares Outstanding, NOT Implied Shares Outstanding)
In 2017, I invested $200 into BioClonetics, the company founded by Charles and Joseph Cotropia. Specifically, I spent $200 on a SAFE (Simple Agreement for Future Equity) via WeFunder.
That SAFE would be converted into actual shares of BioClonetics if BioClonetics received equity financing or experienced a change of control.
For purposes of the SAFE, "equity financing" and "change of control" are defined as follows:
“equity financing” means a bona fide transaction or series of transactions with the principal purpose of raising capital, pursuant to which the Company issues and sells Preferred Stock at a fixed pre-money valuation.
“change of control” means (i) a transaction or series of related transactions in which any “person” or “group” (within the meaning of Section 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended), becomes the “beneficial owner” (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended), directly or indirectly, of more than 50% of the outstanding voting securities of the Company having the right to vote for the election of members of the Company’s board of directors, (ii) any reorganization, merger or consolidation of the Company, other than a transaction or series of related transactions in which the holders of the voting securities of the Company outstanding immediately prior to such transaction or series of related transactions retain, immediately after such transaction or series of related transactions, at least a majority of the total voting power represented by the outstanding voting securities of the Company or such other surviving or resulting entity or (iii) a sale, lease or other disposition of all or substantially all of the assets of the Company.
In 2020, Enzolytics bought BioClonetics. However, Charles Cotropia said that this purchase was NOT a change of control of BioClonetics because the people in charge of BioClonetics would control Enzolytics and Enzolytics would control BioClonetics.
Charles gave 3 options to each investor who had a BioClonetics SAFE.
1) The investor would take a repayment of the investor's original BioClonetics investment with 2% annual interest.
2) The investor would get one Preferred Series D share of Enzolytics for every $5 invested into BioClonetics. After one year, the investor would get 120 shares of Enzolytics Common Stock for every Preferred Series D share of Enzolytics.
3) The investor's BioClonetics SAFE would become an Enzolytics SAFE. In other words, Enzolytics would take over all of BioClonetics's obligations under the SAFE. So, the Enzolytics SAFE would be converted into actual shares of Enzolytics if Enzolytics received equity financing or experienced a change of control.
Option 1 would give me $212, a paltry $12 in profit.
Option 2 would give me 4800 shares of Enzolytics Common Stock.
With option 3, I would get over 81000 shares of Enzolytics Common Stock if Enzolytics experienced a change of control.
In January 2021, I chose option 3.
My questions are as follows:
1) Since January 2021, has Enzolytics received equity financing or experienced a change of control?
2) I invested into BioClonetics because of Charles Cotropia's Clone 3. Which company currently has possession of Clone 3?
If Charles has taken Clone 3 away from Enzolytics, is Charles's action legal? Will there be some kind of class-action lawsuit against Charles as a result of his action?
3) Are any Enzolytics investors currently suing Enzolytics for any reason at all?
4) Other than myself, are any members of this forum holding an Enzolytics SAFE?
Thank you.
ENZC, BioClonetics: Will equity financing or buyout occur?
I got into this ENZC situation by investing $200 into BioClonetics, the company founded by Charles and Joseph Cotropia. Specifically, I spent $200 on a SAFE (Simple Agreement for Future Equity) via WeFunder.
That SAFE would be converted into actual shares of BioClonetics if BioClonetics received equity financing or experienced a change of control.
In 2020, ENZC bought BioClonetics. However, Charles Cotropia said that this was not a change of control because the shareholders of BioClonetics would control ENZC and ENZC would control BioClonetics.
Charles said that ENZC would take over all of BioClonetics's obligations under the SAFE.
So, for me to get ENZC shares, ENZC will have to receive equity financing or experience a change of control (such as a buyout).
So, will ENZC receive equity financing or experience a change of control (such as a buyout) anytime soon?
In 2017, I invested $200 into BioClonetics, the company founded by Charles and
Joseph Cotropia. Specifically, I spent $200 on a SAFE (Simple Agreement for Future Equity) via WeFunder.
That SAFE would be converted into actual shares of BioClonetics if BioClonetics
received equity financing or experienced a change of control.
In 2020, Enzolytics bought BioClonetics. However, Charles Cotropia said that this
was not a change of control because the shareholders of BioClonetics would control Enzolytics and Enzolytics would control BioClonetics.
Charles said that Enzolytics would take over all of BioClonetics's obligations under the SAFE.
So, for me to get Enzolytics shares, Enzolytics would have to receive equity financing or experience a change of control.
So, what are the odds that Enzolytics will receive equity financing or experience a change of control (such as a buyout)? Will either of these things happen anytime
soon?
Here is some news about Eli Lilly's monoclonal antibody against Covid-19:
https://www.statnews.com/2021/01/21/eli-lilly-says-its-monoclonal-antibody-prevented-covid-19-in-clinical-trial/
So, are you saying that Enzolytics can not go to a higher exchange until all of the SAFEs and other convertible notes are converted into Enzolytics common stock?
If ENZC is uplisted, is that an IPO?
According to the SAFE (simple agreement for future equity) that I bought on Wefunder, an IPO is defined as "the closing of the Company’s first firm commitment underwritten initial public offering of Common Stock pursuant to a registration statement filed under the Securities Act".
If ENZC is uplisted from OTC to the NYSE or the NASDAQ, would that uplisting be an IPO as defined in the SAFE?
What are the chances of ENZC being acquired by a company like Eli Lilly?
I'm a Wefunder investor, and I have a SAFE (simple agreement for future equity). Charles Cotropia has given us Wefunder investors a choice.
If I choose Preferred D Series shares and these shares are ultimately converted into ENZC common stock, then I will get a certain number of shares of ENZC common stock. However, if I hold on to my SAFE and ENZC is acquired, then that acquisition will be a liquidity event and I will get a MUCH LARGER number of ENZC shares. Of course, if I hold on to the SAFE and ENZC is never acquired and never receives Series A financing, then I will be stuck with the SAFE (and no stock) forever.